biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > True Story

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Jan 24, 2023 1:45pm

84 Views

Post# 35242786

RE:RE:RE:RE:RE:RE:RE:True Story

I also want to point out, uncle, that when I am accused of destroying people's lives, and that is a general theme pounded out by some posters, over and over, then I am going to point out that I warned of many things over the years. I never even accepted with certainty that xB3 worked.

That's what "if xB3 works as hoped..." means. It's still a question and will remain so until an xB3 drug is approved by the FDA or some other drug agency.

This why I say that you're not ambitious or knowledgeable enough to follow the intent and logic of my posts. I know that because of what you accuse me of.

jd

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management